Repligen | RGEN - Equity Capital And Reserves


Repligen reported $2.11B in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Agilent USD 7.12B 214M Mar/2026
Align Technology USD 4.23B 83.03M Jun/2026
Bio Techne USD 2.09B 74.32M Mar/2026
BioMarin Pharmaceutical USD 6.32B 109.58M Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Bruker USD 2.5B 46.3M Mar/2026
Charles River Laboratories USD 2.84B 59.06M Jun/2026
Danaher USD 52.58B 368M Jun/2026
Dentsply International USD 1.35B 33M Jun/2026
General Electric Aerospace USD 17.64B 417M Jun/2026
Henry Schein USD 3.16B 109M Jun/2026
Illumina USD 2.84B 162M Jun/2026
IQVIA Holdings USD 6.17B 50M Jun/2026
Mettler Toledo International USD 12.82M 54.71M Jun/2026
Myriad Genetics USD 303.9M 33.5M Jun/2026
OraSure Technologies USD 313.32M 27.5M Mar/2026
Pacific Biosciences Of California USD -33.21M 35.58M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Repligen USD 2.11B 6.57M Jun/2026
Revvity USD 7.18B 67.62M Mar/2026
Standard Biotools USD 561.12M 136.83M Mar/2026
Thermo Fisher Scientific USD 51.93B 1.6B Mar/2026
Waters USD 15.29B 12.73B Mar/2026
West Pharmaceutical Services USD 2.99B 200K Jun/2026